-
Views
-
Cite
Cite
Fariba Behbod, Jeffrey M. Rosen, Will cancer stem cells provide new therapeutic targets?, Carcinogenesis, Volume 26, Issue 4, April 2005, Pages 703–711, https://doi.org/10.1093/carcin/bgh293
- Share Icon Share
Abstract
This review presents a brief synopsis of recent progress in the area of cancer stem cells, with emphasis on leukemia and breast cancer, and discusses potential limitations to accomplishing the ultimate goal of eradicating residual disease in cancer.
ALL, acute lymphoblastic leukemia, AML, acute myeloid leukemia, BCRP1, Breast Cancer Resistance Protein-1, CALLA, Acute Lymphoblastic Leukemia Common Antigen, CLP, committed lymphoid progenitor, CMP, common myeloid progenitors, EMA, Epithelial Membrane Antigen, EpCAM, epithelial cell adhesion molecule, ESA, epithelial-specific antigen, GMP, granulocytic/monocytic-restricted progenitors, Hh, Hedgehog, Hox , homeobox , HSCs, hematopoietic stem cells, LRP, Lung Resistance-Related Protein, LT, long-term progenitors, MEP, megakaryocytic/erythroid-restricted progenitors, MLL - ENL , Mixed Lineage Leukemia–Eleven Nineteen Leukemia , MMTV-Wnt-1, mouse mammary tumor virus promoter-driven Wnt-1, MUC-1, sialomucin, NOD/SCID, non-obese diabetic/severe combined immunodeficient, PDGF, Platelet-Derived Growth Factor, PTC-1, Patched-1, Sca-1, stem cell antigen-1, SL-IC, SCID leukemia-initiating cells, SP, side population, ST, short-term progenitors
Carcinogenesis vol.26 no.4 © Oxford University Press 2004; all rights reserved.
Issue Section:
Review
You do not currently have access to this article.